ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA began operations in 2005 and is headquartered in Broomfield, Colorado.
On January 27, 2009, ARCA biopharma merged with Nuvelo, Inc., to create a new cardiovascular focused company, with an experienced cardiovascular leadership team significantly increased resources, and a pipeline of drug candidates in development. The new Company is named ARCA biopharma, Inc. and trades on the Nasdaq Global Market under the symbol ABIO. Read about the merger in the press release